Joint detection of serum NLR,PSA and MMP26 in differentiating prostate cancer from benign prostatic hyperplasia

WANG Yi-jin; LI Qiang; FU Guang-bo

doi:10.13263/j.cnki.nja.2025.05.005

Abstract：Objective:To explore the application value of joint detection of serum neutrophil-to-lymphocyte ratio(NLR),pros-tate-specific antigen(PSA)and MMP26 in differentiating prostate cancer(PCa)from benign prostatic hyperplasia(BPH).Meth-ods:A total of 61 PCa patients(PCa group)and 63 BPH patients(BPH group)who were treated in The Affiliated Huaian Hospital of Xuzhou Medical University from May 2022 to May 2024 were retrospectively included.The relevant clinical data of all subjects were collected with the serum NLR,PSA and MMP26 levels being detected.Multivariate logistic regression analysis was used to analyze the influencing factors in differentiating PCa from BPH.The receiver operating characteristic(ROC)curve was used to evaluate the diag-nostic value of serum NLR,PSA and MMP26 in differentiating PCa from BPH.Results:The levels of TC and LDL-C in the PCa group were higher than those in the BPH group.And the level of HDL-C in the PCa group was lower than that in the BPH group(P＜0.05).The serum levels of NLR,PSA and MMP26 in the PCa group were higher than those in the BPH group(P＜0.05).The re-sults of multivariate logistic regression analysis showed that NLR,PSA and MMP26 were risk factors for the diagnosis of PCa in patients(P＜0.05).The ROC results showed that the area under the curve(AUC)of NLR,PSA MMP26 and joint diagnosis in the identifica-tion of PCa was 0.804,0.800,0.809 and 0.905,respectively.The comparison results of AUC showed that the joint diagnosis was su-perior to the single diagnosis(Z=2.262,2.177,2.002,P＜0.05).Conclusion:The joint detection of serum NLR,PSA and MMP26 has significant application value in the differentiation of PCa and BPH,which is expected to become an effective tool for early screening and diagnosis of PCa.